Liquidia Corp reported insider transactions by its finance and operations chief in a Form 4 filed with the Securities and Exchange Commission. On April 14 and April 15, 2026, Michael Kaseta, serving as both Chief Financial Officer and Chief Operating Officer, exercised incentive stock options and sold a portion of his holdings.
The filing shows Kaseta exercised 89,971 shares of Common Stock under incentive stock options at an exercise price of $2.79 per share, for a total cost of $251,019. Following the exercise, Kaseta sold 139,390 shares of common stock. Those sales were executed at prices in the range of $40.00 to $40.1409, generating proceeds of roughly $5.7 million.
At the time of reporting, Liquidia shares were trading at $41.40. The company’s stock has risen sharply over the last 12 months, achieving a total return of 202% over that period. Separately, an InvestingPro analysis cited in the filing indicates that the stock remains undervalued despite the substantial rally and that the service provides additional valuation tools and tips to subscribers, including access to 13 extra tips and broader financial metrics for LQDA.
The insider transactions coincide with Liquidia Technologies’ release of fourth-quarter 2025 financial results, which presented a mixed picture. The company reported $90.1 million in revenue attributable to its Yutrepia drug, representing 74% quarter-over-quarter growth for that product. Revenue exceeded expectations, yet earnings per share fell short of forecasts, and the EPS miss corresponded with a decline in the company’s share price following the announcement.
Despite the EPS shortfall, several analysts adjusted their valuations and ratings following the quarter. H.C. Wainwright raised its price target to $55, while BTIG increased its target to $50, both citing the Yutrepia launch and the company’s pathway toward profitability. BofA Securities reaffirmed a Buy rating, noting Liquidia’s competitive position in the prostacyclin treatment area. Raymond James maintained a Strong Buy rating and set a $47 target, observing that Yutrepia’s early launch performance was comparable to another treatment’s initial rollout.
Liquidia has also provided revenue guidance that projects annual revenues of more than $1 billion in 2027. The combination of strong product revenue growth, an EPS miss in the most recent quarter, active analyst coverage with higher price targets, and the insider transactions reported in mid-April together form the current public picture of the company.
Market participants and observers will note the juxtaposition of robust product revenue and an earnings shortfall, alongside insider option exercise and substantial share sales disclosed in the SEC filing.